Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda’s Brigatinib Bags European OK for 2nd Line ALK-Positive NSCLC
November 29, 2018
- Dissident Shareholder Group Hails Ex-Takeda Chief’s Opposition to Shire Deal
November 29, 2018
- Blincyto, Eybelis Now Available in Japan
November 28, 2018
- Ono Submits Cancer Cachexia Treatment in Japan
November 28, 2018
- Pola Orbis to Transfer All Shares of Pola Pharma to Sun Pharma Global, Aiming to Focus on Beauty Care Business
November 28, 2018
- Sumitomo Dainippon Settles Latuda Patent Lawsuits in US, New 5-Year Biz Plan Due Out Next Spring
November 28, 2018
- Keytruda Continues to Close in on Opdivo in July-September Global Sales
November 27, 2018
- Poteligeo Approved in Europe for Mycosis Fungoides, Sézary Syndrome: Kyowa Kirin
November 27, 2018
- HIV Drug Juluca Gets Japan Approval: ViiV
November 27, 2018
- GSK, Kyowa Kirin Join Hands for HIF-PH Inhibitor Daprodustat
November 26, 2018
- Astellas Grabs License to Gene Therapy JVS-100, with Acquisition also in Cards
November 26, 2018
- Daiichi Sankyo’s FLT3 Inhibitor Quizartinib Earns FDA’s Priority Review Status
November 26, 2018
- Dissident Takeda Shareholders Making Final Pitch to Thwart Shire Buyout
November 26, 2018
- MHLW Approves Label Expansions for Praluent, Tremfya
November 22, 2018
- Mundipharma Obtains Exclusive Rights in Japan from South Korean Firm for Osteoarthritis Cell Therapy
November 22, 2018
- Takeda Voluntary Recalls 7 Narcotic Injectable Products after Confirming Coloring
November 22, 2018
- Takeda Gets European OK for Shire Deal with Strings Attached
November 21, 2018
- Pfizer’s ALK Inhibitor Lorbrena, Shire’s HAE Drug Now Available in Japan
November 21, 2018
- AbbVie Seeks Japan Approval for BCL-2 Inhibitor Venetoclax in CLL
November 21, 2018
- Takeda to Issue US$5.5 Billion in Bonds for Shire Acquisition
November 21, 2018
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…